Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
02:19a KOBE STEEL : Kobelco Angang Auto Steel begins operations
02:14a DENNY : Read Full Release
02:10a COMCAST 2CPS29 : Aptos school gets face-lift from Comcast, volunteers
01:59a NEUREN PHARMACEUTICALS : Appendix 4C - quarterly
01:49a WENDYS : Lake Tapps father, young driver who killed son bond over dream to finish victim's car
01:47a Italy bank fund to own at least 92 percent of Pop Vicenza after cash call
01:42a LIPOSUCTION VS. TUMMY TUCK : Which Is Right for Me?
01:40a DR. BORIS ACKERMAN : Discusses Breast Augmentation After 40
01:39a WISEKEY : Reports its 2015 Financial Results and Provides Business Update
01:39a ACF AUSTRALIAN CONSERVATION FOUNDATION : Coal or coral? Greens plan puts choice in focus
Latest news
Advertisement
Hot News 
ANDALAS ENERGY AND POWER : Issue of Zero Coupon Loan Note
6D GLOBAL TECHNOLOGIES, INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AVOLON : sustains strong performance as fleet increases to over 400 aircraft
PETRO MATAD : Expecting "Highly Material" Compensation From Partner
HML : Director Dealing April 2016
Most Read News
07:05p Inbox Blueprint 2.0 – Anik Singal Launches an Easy to Follow Online Marketing Program for Beginners in Email Marketing
07:39p ACF AUSTRALIAN CONSERVATION FOUNDATION : Coal or coral? Greens plan puts choice in focus
07:42p LIPOSUCTION VS. TUMMY TUCK : Which Is Right for Me?
07:38p Dr. Richard Balikian Now Can Treat Acne Scars With Lasers and Fillers
07:40p DR. BORIS ACKERMAN : Discusses Breast Augmentation After 40
Most recommended articles
07:47p Italy bank fund to own at least 92 percent of Pop Vicenza after cash call
07:18p PHILIP GREEN : UK lawmakers ask Philip Green to testify in BHS pensions inquiry
06:16p WARREN BUFFETT : Buffett says hedge funds are a bad deal for investors
05:59p Buffett, Munger slam Valeant; drugmaker turned into 'a sewer'
05:29p Buffett, Munger slam Valeant; drugmaker turned into 'a sewer'